Free Trial

Alnylam Pharmaceuticals (ALNY) SEC Filings & 10K Form

Alnylam Pharmaceuticals logo
$250.59 -0.41 (-0.16%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$248.84 -1.76 (-0.70%)
As of 02/21/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Alnylam Pharmaceuticals SEC Filings

DateFilerForm TypeView
02/13/2025
1:14 PM
Alnylam Pharmaceuticals (Subject)
Capital Research Global Investors (Filed by)
Form SCHEDULE 13G
02/13/2025
7:31 AM
Alnylam Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/13/2025
7:09 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2025
3:01 PM
Alnylam Pharmaceuticals (Subject)
Garg Pushkal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2025
3:17 PM
Alnylam Pharmaceuticals (Subject)
SHARP PHILLIP A (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2025
6:31 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/13/2024
3:13 PM
Alnylam Pharmaceuticals (Issuer)
Garg Pushkal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:20 PM
Alnylam Pharmaceuticals (Issuer)
Fitzgerald Kevin Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:21 PM
Alnylam Pharmaceuticals (Issuer)
Tanguler Tolga (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:21 PM
Alnylam Pharmaceuticals (Issuer)
Poulton Jeffrey V. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:22 PM
Alnylam Pharmaceuticals (Issuer)
Garg Pushkal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:22 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
3:06 PM
Alnylam Pharmaceuticals (Subject)
Fitzgerald Kevin Joseph (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/08/2024
9:34 AM
Alnylam Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
10/31/2024
7:10 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/31/2024
7:22 AM
Alnylam Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/03/2024
3:11 PM
Alnylam Pharmaceuticals (Issuer)
Hesslein Robert W. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2024
7:01 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
4:10 PM
Alnylam Pharmaceuticals (Subject)
Greenstreet Yvonne (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/12/2024
8:40 AM
Alnylam Pharmaceuticals (Subject)
FMR LLC (Filed by)
Form SC 13G/A
08/02/2024
7:01 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/01/2024
7:22 AM
Alnylam Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2024
7:11 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/12/2024
7:02 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/11/2024
3:40 PM
Alnylam Pharmaceuticals (Subject)
Greenstreet Yvonne (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/05/2024
9:24 AM
Alnylam Pharmaceuticals (Subject)
BAILLIE GIFFORD & CO (Filed by)
Form SC 13G/A
05/31/2024
6:00 PM
Alnylam Pharmaceuticals (Issuer)
SCHULMAN AMY W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
3:34 PM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
7:21 AM
Alnylam Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/02/2024
7:11 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/01/2024
3:37 PM
Alnylam Pharmaceuticals (Filer)
Form ARS
04/01/2024
3:31 PM
Alnylam Pharmaceuticals (Filer)
Form DEF 14A
03/04/2024
3:33 PM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/29/2024
3:16 PM
Alnylam Pharmaceuticals (Issuer)
Franchini Indrani Lall (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:17 PM
Alnylam Pharmaceuticals (Issuer)
Garg Pushkal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:18 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:18 PM
Alnylam Pharmaceuticals (Issuer)
Poulton Jeffrey V. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:18 PM
Alnylam Pharmaceuticals (Issuer)
Tanguler Tolga (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:00 PM
Alnylam Pharmaceuticals (Subject)
SHARP PHILLIP A (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ALNY) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners